MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure?
作者信息
Feinberg Mark W
机构信息
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Trends Cardiovasc Med. 2016 Feb;26(2):111-4. doi: 10.1016/j.tcm.2015.06.001. Epub 2015 Jun 12.
Abstract
摘要
相似文献
1
MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure?微小RNA作为病理生理靶点：心力衰竭个性化医疗中一个新兴的关联点？
Trends Cardiovasc Med. 2016 Feb;26(2):111-4. doi: 10.1016/j.tcm.2015.06.001. Epub 2015 Jun 12.
2
MicroRNAs in heart failure: from biomarker to target for therapy.微小 RNA 在心力衰竭中的作用：从生物标志物到治疗靶点。
Eur J Heart Fail. 2016 May;18(5):457-68. doi: 10.1002/ejhf.495. Epub 2016 Feb 11.
3
microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.微小RNA与个性化医疗：评估其作为癌症生物标志物的潜力
Adv Exp Med Biol. 2015;888:5-15. doi: 10.1007/978-3-319-22671-2_2.
4
Heart failure and atrial fibrillation: Can we break this nexus?心力衰竭与心房颤动：我们能否打破这种联系？
Int J Cardiol. 2018 Feb 1;252:142-143. doi: 10.1016/j.ijcard.2017.11.043.
5
Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF?微小RNA能否成为区分射血分数保留的心力衰竭与射血分数降低的心力衰竭的生物标志物？
Int J Cardiol. 2014 Aug 20;175(3):395-9. doi: 10.1016/j.ijcard.2014.06.027. Epub 2014 Jun 28.
6
Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.从心力衰竭的常规治疗向基于生物标志物的个性化精准医学转变：行动呼吁。
Eur Heart J. 2018 Aug 7;39(30):2793-2799. doi: 10.1093/eurheartj/ehx027.
7
Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.生物标志物在心力衰竭临床试验中的既定作用与新兴作用
Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.115.002528.
8
Artificial heart pumps: bridging the gap between science, technology and personalized medicine by relational medicine.人工心脏泵：通过关系医学弥合科学、技术与个性化医疗之间的差距。
Future Cardiol. 2017 Jan;13(1):23-32. doi: 10.2217/fca-2016-0020. Epub 2016 Dec 19.
9
Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it.个性化医疗与心力衰竭住院治疗：如果我们了解它，我们可能成功治疗它。
Eur J Heart Fail. 2019 Jun;21(6):699-702. doi: 10.1002/ejhf.1463. Epub 2019 Apr 11.
10
Metabolomics - A wide-open door to personalized treatment in chronic heart failure?代谢组学——慢性心力衰竭个性化治疗的一扇敞开大门？
Int J Cardiol. 2016 Sep 15;219:156-63. doi: 10.1016/j.ijcard.2016.06.022. Epub 2016 Jun 14.
引用本文的文献
1
MicroRNA Regulation of Atherosclerosis.微小RNA对动脉粥样硬化的调控
Circ Res. 2016 Feb 19;118(4):703-20. doi: 10.1161/CIRCRESAHA.115.306300.
本文引用的文献
1
Targeting microRNAs in heart failure.靶向心力衰竭中的 microRNAs。
Trends Cardiovasc Med. 2016 Feb;26(2):99-110. doi: 10.1016/j.tcm.2015.05.008. Epub 2015 May 30.
2
An emerging role for the miR-26 family in cardiovascular disease.微小RNA-26家族在心血管疾病中的新作用。
Trends Cardiovasc Med. 2014 Aug;24(6):241-8. doi: 10.1016/j.tcm.2014.06.003. Epub 2014 Jun 12.
3
MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade.MicroRNA-133 调节β1-肾上腺素能受体转导级联。
Circ Res. 2014 Jul 7;115(2):273-83. doi: 10.1161/CIRCRESAHA.115.303252. Epub 2014 May 7.
4
Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.循环 miR-29a 是肥厚型心肌病患者心肌肥厚和纤维化的唯一生物标志物，其他上调的 microRNAs 也是如此。
J Am Coll Cardiol. 2014 Mar 11;63(9):920-7. doi: 10.1016/j.jacc.2013.09.041. Epub 2013 Oct 23.
5
MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.microRNA-26a 通过靶向 BMP/SMAD1 信号通路调节病理性和生理性血管生成。
Circ Res. 2013 Nov 8;113(11):1231-41. doi: 10.1161/CIRCRESAHA.113.301780. Epub 2013 Sep 18.
6
The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation.缺氧诱导的 microRNA 簇 miR-199a∼214 靶向心肌 PPARδ，损害线粒体脂肪酸氧化。
Cell Metab. 2013 Sep 3;18(3):341-54. doi: 10.1016/j.cmet.2013.08.009.
7
Macrophage microRNA-155 promotes cardiac hypertrophy and failure.巨噬细胞 microRNA-155 促进心肌肥大和衰竭。
Circulation. 2013 Sep 24;128(13):1420-32. doi: 10.1161/CIRCULATIONAHA.112.001357. Epub 2013 Aug 16.
8
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告
Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.
9
Treatment of HCV infection by targeting microRNA.针对 microRNA 治疗 HCV 感染。
N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.
10
MicroRNA-34a regulates cardiac ageing and function.miRNA-34a 调控心脏衰老和功能。
Nature. 2013 Mar 7;495(7439):107-10. doi: 10.1038/nature11919. Epub 2013 Feb 20.
Zotero 插件